Company intelligence / Profile preview

Pearl Bio

Cambridge, Massachusetts, United Statespearlbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Pearl Bio is developing a platform that uses genomically recoded organisms and ribosome engineering to create novel biologics with diverse chemistries previously inaccessible. The company has entered a collaboration with Merck to discover biologic therapies comprising non-standard amino acids.

Therapeutic areas: Oncology
Modalities: BiologicsMulti-functionalized biologicsBiomaterials
Industry: Biotech

Partnerships

Merck (up to $1 billion collaboration deal)

Beyond the preview

Go deeper on Pearl Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pearl Bio.

Explore the full profile